LEADER 01898nam  2200385z- 450 
001 9910346739803321
005 20231214133454.0
035   $a(CKB)4920000000094316
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/44424
035   $a(EXLCZ)994920000000094316
100   $a20202102d2019      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aCurrent Progress and Challenges in the Development of a Hepatitis C Virus Vaccine
210   $cFrontiers Media SA$d2019
215   $a1 electronic resource (128 p.)
225 1 $aFrontiers Research Topics
311   $a2-88945-714-1 
330   $aMore than 70 million people worldwide are infected with hepatitis C virus, a major cause of liver cirrhosis, liver failure and hepatocellular carcinoma world-wide. In the last decade, this cancer has emerged as the second leading cause of cancer death and the global burden is increasing by two million new infections per year, mainly due to injection drug use. An effective vaccine will be the most effective means to contain the spread of this virus worldwide. The articles in this Research Topic describe the progress that has been made towards a preventive vaccine and the challenges that still need to be overcome to ultimately achieve this goal.
610   $aConformational epitopes
610   $ahumoral immunity
610   $aConformational structures
610   $aneutralizing antibodies
610   $aVaccine
610   $aHepatitis C virus
610   $ahypervariability and flexibility
700   $aThomas F. Baumert$4auth$01318734
702   $aSteven K.H. Foung$4auth
906   $aBOOK
912   $a9910346739803321
996   $aCurrent Progress and Challenges in the Development of a Hepatitis C Virus Vaccine$93033499
997   $aUNINA